Trial Profile
A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2014
Price :
$35
*
At a glance
- Drugs LD02GIFRO (Primary)
- Indications Postoperative ileus
- Focus Therapeutic Use
- Sponsors LG Life Sciences
- 08 Apr 2014 New trial record